Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study
Authors
Keywords
-
Journal
ARTHRITIS CARE & RESEARCH
Volume 69, Issue 3, Pages 347-355
Publisher
Wiley
Online
2016-10-07
DOI
10.1002/acr.23111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
- (2016) Désirée van der Heijde et al. Arthritis & Rheumatology
- European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
- (2015) L Gossec et al. ANNALS OF THE RHEUMATIC DISEASES
- Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study
- (2015) F. Behrens et al. JOURNAL OF RHEUMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
- (2015) Ulrich Mrowietz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biologic Therapy for Psoriatic Arthritis
- (2015) Philip J. Mease RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- SAT0142 Immunogenicity of the Novel Anti-Il-17A Antibody, Secukinumab, with Intravenous and Subcutaneous Dosing Regimens in Healthy Subjects and Patients
- (2014) U. Klein et al. ANNALS OF THE RHEUMATIC DISEASES
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
- (2014) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
- (2014) Philip J. Mease et al. DRUGS
- Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
- (2014) Mark G. Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study
- (2013) Karen Minde Fagerli et al. ANNALS OF THE RHEUMATIC DISEASES
- The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study
- (2013) Karen Minde Fagerli et al. ANNALS OF THE RHEUMATIC DISEASES
- The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics
- (2013) Laura C. Coates et al. RHEUMATOLOGY
- Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States
- (2013) April W. Armstrong et al. JAMA Dermatology
- Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study
- (2012) P. Rich et al. BRITISH JOURNAL OF DERMATOLOGY
- Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
- (2009) Amr A Saad et al. ARTHRITIS RESEARCH & THERAPY
- Treatment recommendations for psoriatic arthritis
- (2008) C T Ritchlin et al. ANNALS OF THE RHEUMATIC DISEASES
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alice Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now